Contact Us

Follow

Revolutionizing Cancer Treatment with Ivonescimab

"Summit provides leadership with proven success in oncology development, regulatory approvals, and commercialization."

Bob Duggan

Chief Executive Officer

Overview

At the heart of Summit Therapeutics’ work is a powerful mission: to build a sustainable healthcare organization devoted to creating transformative medicines designed to improve quality of life, increase life duration, and address serious healthcare needs. This ambitious goal is underpinned by an exceptional blend of scientific and administrative expertise, as well as a clear focus on developing rapid, cost-efficient products, and engaging commercial partners when necessary.

A shining example of their ongoing mission is Ivonescimab, a novel drug designed to address the critical health issue of cancer. What makes Ivonescimab unique is that it combines two major anti-cancer actions into one single molecule – stimulating the immune system to fight cancer and inhibiting the formation of blood vessels that support tumor growth. This dual-action approach could potentially be a game-changer in cancer treatment.

Technology

Summit Therapeutics is currently focusing on applying Ivonescimab to treat a type of lung cancer known as NSCLC. If all goes according to plan, the company expects to start clinical trials by the middle of 2023, marking an important milestone in its mission to resolve serious healthcare needs.

In terms of global recognition, Ivonescimab has already made a significant impact. It received the “Breakthrough Therapy Designation” in China, a status reserved for promising drugs, for three different applications. This acknowledgment bolsters confidence in the potential effectiveness of Ivonescimab.

Moreover, the drug is undergoing trials in China and Australia for the treatment of various solid tumors. This includes a substantial Phase III clinical trial focusing on patients with NSCLC carrying an EGFR mutation and who have not responded to previous treatments.

The ethos of Summit Therapeutics extends beyond the development of new therapies. The team is committed to shouldering the full responsibility of successful design, development, regulatory approval, and commercialization. They constantly strive to expand their knowledge, capabilities, and wellbeing for all stakeholders and shareholders involved.

Founded in 2003, Summit Therapeutics is listed on the Nasdaq Global Market under the symbol ‘SMMT.’ The company is based in Menlo Park, California, with additional offices in Oxford, UK. With its forward-thinking approach and commitment to revolutionary healthcare solutions like Ivonescimab, Summit Therapeutics is undoubtedly setting new standards in the battle against cancer.

Key Dates

Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023

04 Jun 2023

Go to link

Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)

09 May 2023

Go to link

Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody

20 Jan 2023

Go to link

Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

05 Jan 2023

Go to link

Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody

12 Jun 2022

Go to link

Summit appoints Robert W. Duggan as Chief Executive Officer

14 Apr 2020

Go to link

Summit Therapeutics gets US$50mln backing from biotech billionaire Bob Duggan

06 Dec 2019

Go to link

Effect of broad vs. narrow-spectrum Clostridioides Difficile treatment on human stool bile acid composition over time

07 Oct 2019

Go to link

Narrow-spectrum antibiotic treatment of Clostridium Difficile infection improves preservation of intestinal metabolic profile

07 Oct 2019

Go to link

Quality of life changes in patients with Clostridium Difficile Infection (CDI): a Randomized, Double-blind Trial of Ridinilazole (RDZ) compared to Vancomycin (VAN)

03 Oct 2019

Go to link

Combating resistance while maintaining innovation: the future of anti-microbial stewardship

18 Sep 2019

Go to link

In vivo proof of concept for a novel small molecule inhibitor of bacterial Lipoprotein transport targeting Enterobacteriaceae

05 Sep 2019

Go to link

From new mechanisms to new standards of care

24 Jun 2019

Go to link

Novel small-molecule inhibitors of bacterial Lipoprotein transport with potent antimicrobial activity against Enterobacteriaceae

14 Apr 2019

Go to link

Robert Duggan invests $25mn into Summit

17 Dec 2018

Go to link

A novel small molecule antibiotic for the treatment of Neisseria gonorrhoeae

13 Nov 2018

Go to link

Ridinilazole for Clostridium Difficile Infection: human gut microbiome profiles from a phase 2 clinical trial

03 Oct 2018

Go to link

Summit Therapeutics was founded

01 Jan 2003

Go to link

Media

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023

11 May 2023

Go to link

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022

04 Mar 2023

Go to link

Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering

03 Mar 2023

Go to link

Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022

09 Nov 2022

Go to link

Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022

09 Nov 2022

Go to link

Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2020

29 Sep 2020

Go to link

Summit announces effectiveness of scheme of arrangement and completion of redomiciliation to Delaware, USA

18 Sep 2020

Go to link

Summit Therapeutics announces U.K. court approval for redomiciliation to Delaware, USA

17 Sep 2020

Go to link

Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids

29 Jul 2020

Go to link

Pharmacyclics billionaire Bob Duggan takes the helm of another biotech — and he faces an even bigger uphill climb this time

14 Apr 2020

Go to link

Billionaire Robert Duggan’s New Biotech Chapter: An Antibiotics Quest

27 Feb 2020

Go to link

Summit Therapeutics appoints controlling shareholder, biotech billionaire Bob Duggan as its executive chairman

26 Feb 2020

Go to link

Summit Therapeutics announces £38M fundraising success

02 Jan 2020

Go to link

Summit Therapeutics’ Glyn Edwards talks about US$50mln backing and Ridinilazole progress

09 Dec 2019

Play Video

Billionaire’s big investment shows renewed faith in drugs company

07 Dec 2019

Go to link

Summit Therapeutics gets US$50mln backing from biotech billionaire Bob Duggan

06 Dec 2019

Go to link

Biotech firms fight panic over spread of superbugs

08 Nov 2019

Go to link

Summit Therapeutics to participate in panel sessions at the World Antimicrobial Resistance Congress.

06 Nov 2019

Go to link

Summit Therapeutics recognises C Difficile awareness month

04 Nov 2019

Go to link

Summit Therapeutics CEO says anti microbial resistance will be as big a problem as climate change

25 Oct 2019

Go to link

Can the rally in Summit Therapeutics shares continue?

22 Oct 2019

Go to link

Summit Therapeutics shares rise on phase II c.difficile data

03 Oct 2019

Go to link

Summit announces publication of editorial in future microbiology advocating for innovation in antibiotic development to drive stewardship focus on improving patient outcomes

17 Sep 2019

Go to link

Summit Therapeutics well placed in the race to find next-generation antibiotic

17 Apr 2019

Go to link

Summit presents in vivo proof of concept data for new mechanism antibiotics targeting Enterobacteriaceae in oral session at ECCMID 2019

14 Apr 2019

Go to link

Summit Therapeutics expands drug pipeline with antibiotics targeting deadly bacteria

04 Apr 2019

Go to link

Summit’s SMT-571 potent against over 200 clinical isolates of Neisseria Gonorrhoeae, including numerous multi- and extensively-drug resistant strains, in published preclinical data

25 Feb 2019

Go to link

Summit Therapeutics to present at the BIO CEO & Investor Conference

08 Feb 2019

Go to link

Precision antibiotic improves outcome of gut infections in phase II

03 Aug 2018

Go to link

US billionaire Robert Duggan to invest US$25mln into Summit Therapeutics

10 Jul 2018

Go to link

Cambridge biotech Summit pivots from failed trial, layoffs with $4.5M from CARB-X

10 Jul 2018

Go to link

Disappointment for Summit Therapeutics as rare disease drug flops in trials

27 Jun 2018

Go to link

Summit confirms £10mln acquisition of antibiotics discovery group Discuva

27 Dec 2017

Go to link

"Certainly a resident tendency to expect the best possible outcome fuels the energy always required to make a meaningful difference for the betterment of existing conditions.”

Bob Duggan

Chief Executive Officer

Key Dates

Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023

04 Jun 2023

Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)

09 May 2023

Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody

20 Jan 2023

Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

05 Jan 2023

Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody

12 Jun 2022

Summit appoints Robert W. Duggan as Chief Executive Officer

14 Apr 2020

Summit Therapeutics gets US$50mln backing from biotech billionaire Bob Duggan

06 Dec 2019

Effect of broad vs. narrow-spectrum Clostridioides Difficile treatment on human stool bile acid composition over time

07 Oct 2019

Narrow-spectrum antibiotic treatment of Clostridium Difficile infection improves preservation of intestinal metabolic profile

07 Oct 2019

Quality of life changes in patients with Clostridium Difficile Infection (CDI): a Randomized, Double-blind Trial of Ridinilazole (RDZ) compared to Vancomycin (VAN)

03 Oct 2019

Combating resistance while maintaining innovation: the future of anti-microbial stewardship

18 Sep 2019

In vivo proof of concept for a novel small molecule inhibitor of bacterial Lipoprotein transport targeting Enterobacteriaceae

05 Sep 2019

From new mechanisms to new standards of care

24 Jun 2019

Novel small-molecule inhibitors of bacterial Lipoprotein transport with potent antimicrobial activity against Enterobacteriaceae

14 Apr 2019

Robert Duggan invests $25mn into Summit

17 Dec 2018

A novel small molecule antibiotic for the treatment of Neisseria gonorrhoeae

13 Nov 2018

Ridinilazole for Clostridium Difficile Infection: human gut microbiome profiles from a phase 2 clinical trial

03 Oct 2018

Summit Therapeutics was founded

01 Jan 2003

Media

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023

11 May 2023

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022

04 Mar 2023

Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering

03 Mar 2023

Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022

09 Nov 2022

Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022

09 Nov 2022

Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2020

29 Sep 2020

Summit announces effectiveness of scheme of arrangement and completion of redomiciliation to Delaware, USA

18 Sep 2020

Summit Therapeutics announces U.K. court approval for redomiciliation to Delaware, USA

17 Sep 2020

Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids

29 Jul 2020

Pharmacyclics billionaire Bob Duggan takes the helm of another biotech — and he faces an even bigger uphill climb this time

14 Apr 2020

Billionaire Robert Duggan’s New Biotech Chapter: An Antibiotics Quest

27 Feb 2020

Summit Therapeutics appoints controlling shareholder, biotech billionaire Bob Duggan as its executive chairman

26 Feb 2020

Summit Therapeutics announces £38M fundraising success

02 Jan 2020

Summit Therapeutics’ Glyn Edwards talks about US$50mln backing and Ridinilazole progress

09 Dec 2019

Billionaire’s big investment shows renewed faith in drugs company

07 Dec 2019

Summit Therapeutics gets US$50mln backing from biotech billionaire Bob Duggan

06 Dec 2019

Biotech firms fight panic over spread of superbugs

08 Nov 2019

Summit Therapeutics to participate in panel sessions at the World Antimicrobial Resistance Congress.

06 Nov 2019

Summit Therapeutics recognises C Difficile awareness month

04 Nov 2019

Summit Therapeutics CEO says anti microbial resistance will be as big a problem as climate change

25 Oct 2019

Can the rally in Summit Therapeutics shares continue?

22 Oct 2019

Summit Therapeutics shares rise on phase II c.difficile data

03 Oct 2019

Summit announces publication of editorial in future microbiology advocating for innovation in antibiotic development to drive stewardship focus on improving patient outcomes

17 Sep 2019

Summit Therapeutics well placed in the race to find next-generation antibiotic

17 Apr 2019

Summit presents in vivo proof of concept data for new mechanism antibiotics targeting Enterobacteriaceae in oral session at ECCMID 2019

14 Apr 2019

Summit Therapeutics expands drug pipeline with antibiotics targeting deadly bacteria

04 Apr 2019

Summit’s SMT-571 potent against over 200 clinical isolates of Neisseria Gonorrhoeae, including numerous multi- and extensively-drug resistant strains, in published preclinical data

25 Feb 2019

Summit Therapeutics to present at the BIO CEO & Investor Conference

08 Feb 2019

Precision antibiotic improves outcome of gut infections in phase II

03 Aug 2018

US billionaire Robert Duggan to invest US$25mln into Summit Therapeutics

10 Jul 2018

Cambridge biotech Summit pivots from failed trial, layoffs with $4.5M from CARB-X

10 Jul 2018

Disappointment for Summit Therapeutics as rare disease drug flops in trials

27 Jun 2018

Summit confirms £10mln acquisition of antibiotics discovery group Discuva

27 Dec 2017